Published in Cancer Control on July 01, 2007
Role of platelet-derived growth factors in physiology and medicine. Genes Dev (2008) 8.89
Plasma from preeclamptic women increases blood-brain barrier permeability: role of vascular endothelial growth factor signaling. Hypertension (2010) 1.32
Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res (2009) 1.20
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev (2014) 1.09
Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis. Clin Ophthalmol (2013) 1.02
Novel delivery strategies for glioblastoma. Cancer J (2012) 1.01
Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev (2010) 1.00
Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia (2009) 0.99
Delivery of platelet-derived growth factor as a chemotactic factor for mesenchymal stem cells by bone-mimetic electrospun scaffolds. PLoS One (2012) 0.94
Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res (2013) 0.92
Platelet-derived growth factors and their receptors: structural and functional perspectives. Biochim Biophys Acta (2012) 0.91
Shared gene expression alterations in prostate cancer and histologically benign prostate from patients with prostate cancer. Am J Pathol (2012) 0.91
Recruitment and retention: factors that affect pericyte migration. Cell Mol Life Sci (2013) 0.90
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol (2012) 0.88
Zinc protoporphyrin regulates cyclin D1 expression independent of heme oxygenase inhibition. J Biol Chem (2009) 0.86
Use of antivascular endothelial growth factor for diabetic macular edema. Clin Ophthalmol (2010) 0.85
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemother Pharmacol (2010) 0.85
Tumour progression and liver regeneration--insights from animal models. Nat Rev Gastroenterol Hepatol (2013) 0.84
Upregulation of thrombospondin-1 and angiogenesis in an aggressive human pancreatic cancer cell line selected for high metastasis. Mol Cancer Ther (2009) 0.83
Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells. BMC Cancer (2013) 0.81
Giant cavernous hepatic hemangioma shrunk by use of sorafenib. Clin J Gastroenterol (2012) 0.80
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother Pharmacol (2012) 0.80
IGF-1 receptor is down-regulated by sunitinib induces MDM2-dependent ubiquitination. FEBS Open Bio (2011) 0.80
Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol (2014) 0.80
Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient. BMJ Case Rep (2013) 0.79
Platelet-derived growth factor over-expression in retinal progenitors results in abnormal retinal vessel formation. PLoS One (2012) 0.78
Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma. Cancer Gene Ther (2014) 0.78
Molecular targets and targeted therapies in bladder cancer management. World J Urol (2008) 0.78
Paeonol Inhibits Proliferation of Vascular Smooth Muscle Cells Stimulated by High Glucose via Ras-Raf-ERK1/2 Signaling Pathway in Coculture Model. Evid Based Complement Alternat Med (2014) 0.77
Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. J Cancer Res Clin Oncol (2008) 0.76
Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. Onco Targets Ther (2016) 0.75
The Role of PDGFs and PDGFRs in Colorectal Cancer. Mediators Inflamm (2017) 0.75
Inactivation of the ATMIN/ATM pathway protects against glioblastoma formation. Elife (2016) 0.75
Uveitic Macular Edema: Treatment Update. Curr Ophthalmol Rep (2016) 0.75
Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma. Dis Markers (2016) 0.75
Expression Of Selected Pathway-Marker Genes In Human Urothelial Cells Exposed Chronically To A Non-Cytotoxic Concentration Of Monomethylarsonous Acid. Toxicol Rep (2014) 0.75
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol (2008) 2.35
Removing the unknown from the carcinoma of unknown primary. J Clin Oncol (2012) 1.99
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A (2013) 1.88
Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res (2005) 1.65
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem (2004) 1.43
Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr (2011) 1.15
Activated stat-3 in melanoma. Cancer Control (2008) 1.11
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther (2005) 1.11
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res (2009) 1.02
Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res (2010) 1.01
Uncommon manifestations of common malignancies: case 3. Malignant melanoma arising from a spinal nerve root. J Clin Oncol (2004) 0.97
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res (2005) 0.94
Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control (2006) 0.92
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest (2016) 0.89
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res (2007) 0.89
An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second 'primary' tumor. J Cutan Pathol (2011) 0.85
Immunotherapy as part of a multidisciplinary approach to melanoma treatment. Front Biosci (2006) 0.84
Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res (2011) 0.83
State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer. Cancer (2008) 0.80
PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother (2014) 0.80
The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. Drugs (2015) 0.78
Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. Expert Opin Investig Drugs (2011) 0.77
NRAS-mutant melanoma: response to chemotherapy. Arch Dermatol (2011) 0.77
New horizons in melanoma treatment: targeting molecular pathways. Ochsner J (2010) 0.76
BEAM trial: lighting the way ahead? J Clin Oncol (2011) 0.75
Reply to M.-E. Percival et al and L.B. Saltz. J Clin Oncol (2013) 0.75
Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios. Cancer Control (2008) 0.75